[{"data":1,"prerenderedAt":199},["ShallowReactive",2],{"drug-adalimumab":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":22,"regimens":37,"contraindications":101,"warnings":102,"renal":117,"monitoring":118,"interactions":119,"review":120,"examples":123,"atc":124,"iran":126,"usApproval":142,"links":148,"populations":165},"adalimumab",1,{"fa":7,"en":8},"آدالیمومب","Adalimumab","antineoplastic-immunomodulating",{"fa":11,"en":12},"مهارکننده TNF","TNF blocker",[14],{"name":15,"market":16},"Humira","US",[18,19,7,20,21],"humira","هومیرا","cinnora","سینورا",[23],{"id":24,"form":25,"route":26,"label":27,"concentration":28,"markets":32,"refs":33},"pen-40","injection","sc","40 mg\u002F0.4 mL or 40 mg\u002F0.8 mL pen\u002Fsyringe (also 80 mg, 20 mg, 10 mg)",{"amount":29,"unit":30,"perVolumeMl":31},40,"mg",0.4,[16],[34],{"source":35,"section":36},"fda-humira","3",[38,56,72,86],{"id":39,"disease":40,"label":41,"population":44,"type":48,"unit":30,"dose":49,"refs":53},"ra","rheumatoid-arthritis",{"fa":42,"en":43},"آرتریت روماتوئید، پسوریاتیک، اسپوندیلیت — بزرگسال ۴۰ mg یک هفته در میان","RA, PsA, ankylosing spondylitis — adult 40 mg every other week",{"minAge":45},{"value":46,"unit":47},18,"year","notCalculated",{"reason":50},{"fa":51,"en":52},"هر دو هفته یک بار ۴۰ mg زیرجلدی (نه روزانه). در RA بدون متوترکسات ممکن است ۴۰ mg هفتگی یا ۸۰ mg دو هفته یک بار سود بیشتری داشته باشد.","40 mg SC every OTHER WEEK (not daily). In RA without methotrexate some benefit from 40 mg weekly or 80 mg every other week.",[54],{"source":35,"section":55},"2.2",{"id":57,"disease":58,"label":59,"population":62,"type":48,"unit":30,"dose":65,"refs":69},"jia","juvenile-arthritis",{"fa":60,"en":61},"آرتریت ایدیوپاتیک نوجوانان (۲ سال به بالا) — ۱۰\u002F۲۰\u002F۴۰ mg یک هفته در میان بر اساس وزن","JIA (≥2 y) — 10 \u002F 20 \u002F 40 mg every other week by weight",{"minAge":63},{"value":64,"unit":47},2,{"reason":66},{"fa":67,"en":68},"یک هفته در میان: ۱۰ تا \u003C۱۵ kg ← ۱۰ mg؛ ۱۵ تا \u003C۳۰ kg ← ۲۰ mg؛ ≥۳۰ kg ← ۴۰ mg.","Every other week: 10 to \u003C15 kg → 10 mg; 15 to \u003C30 kg → 20 mg; ≥30 kg → 40 mg.",[70],{"source":35,"section":71},"2",{"id":73,"disease":74,"label":75,"population":78,"type":48,"unit":30,"dose":80,"refs":84},"crohn","crohns",{"fa":76,"en":77},"کرون و کولیت اولسروز — بزرگسال: ۱۶۰ mg روز ۱، ۸۰ mg روز ۱۵، سپس ۴۰ mg یک هفته در میان","Crohn’s \u002F UC — adult: 160 mg day 1, 80 mg day 15, then 40 mg every other week",{"minAge":79},{"value":46,"unit":47},{"reason":81},{"fa":82,"en":83},"روز ۱: ۱۶۰ mg (یک روز یا تقسیم در دو روز)؛ روز ۱۵: ۸۰ mg؛ از روز ۲۹: ۴۰ mg یک هفته در میان.","Day 1: 160 mg (one day or split over two days); day 15: 80 mg; from day 29: 40 mg every other week.",[85],{"source":35,"section":71},{"id":87,"disease":88,"label":89,"population":92,"type":48,"unit":30,"dose":94,"refs":98},"hs","hidradenitis",{"fa":90,"en":91},"هیدرادنیت چرکی — بزرگسال: ۱۶۰ mg، ۸۰ mg روز ۱۵، سپس ۴۰ mg هفتگی یا ۸۰ mg دو هفته یک بار","Hidradenitis suppurativa — adult: 160 mg, 80 mg day 15, then 40 mg weekly or 80 mg every other week",{"minAge":93},{"value":46,"unit":47},{"reason":95},{"fa":96,"en":97},"روز ۱: ۱۶۰ mg؛ روز ۱۵: ۸۰ mg؛ از روز ۲۹: ۴۰ mg هفتگی یا ۸۰ mg یک هفته در میان.","Day 1: 160 mg; day 15: 80 mg; from day 29: 40 mg weekly or 80 mg every other week.",[99],{"source":35,"section":100},"2.7",[],[103,110],{"text":104,"refs":107},{"fa":105,"en":106},"هشدار جعبه‌ای: عفونت جدی (سل، قارچی، فرصت‌طلب) و بدخیمی. پیش از شروع تست سل نهفته و در صورت مثبت بودن درمان آن.","Boxed warning: serious infections (TB, fungal, opportunistic) and malignancy. Test for latent TB before starting and treat if positive.",[108],{"source":35,"section":109},"Boxed Warning",{"text":111,"refs":114},{"fa":112,"en":113},"لنفوم و بدخیمی در کودک و نوجوان؛ فعال شدن هپاتیت B؛ نارسایی قلب؛ بیماری دمیلینه‌کننده؛ واکسن زنده نه.","Lymphoma and malignancy in children and adolescents; hepatitis B reactivation; heart failure; demyelinating disease; no live vaccines.",[115],{"source":35,"section":116},"5",[],[],[],{"status":121,"reviewer":122,"date":122},"unverified",null,[],[125],"L04AB04",{"status":127,"forms":128,"refs":137},"registered",[129,133],{"code":130,"en":131,"fa":132},"16164","ADALIMUMAB 40MG\u002F0.8ML INJ","فرآورده تزریقی آدالیمومب ۴۰ میلی‌گرم \u002F ۰٫۸ میلی‌لیتر",{"code":134,"en":135,"fa":136},"52035","ADALIMUMAB 50 mg\u002F1mL 0.4ML INJ","فرآورده تزریقی آدالیمومب ۵۰ میلی‌گرم \u002F ۱ میلی‌لیتر ۰٫۴ میلی‌لیتر",[138],{"source":139,"section":140,"url":141},"darooyab-generic","G-5\u002FAdalimumab","https:\u002F\u002Fwww.darooyab.ir\u002FG-5\u002FAdalimumab",{"kind":143,"refs":144,"id":147},"BLA",[145],{"source":35,"section":146},"SPL approval \u002F marketing category","BLA125057",[149,152,156,160,163],{"kind":150,"url":151,"label":147},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=125057",{"kind":153,"url":154,"label":155},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=4977567e-3525-44ac-9ff5-f1e74b053950","FDA Humira",{"kind":157,"url":158,"label":159},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa603010.html","Adalimumab Injection",{"kind":161,"url":162,"label":125},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=L04AB04",{"kind":164,"url":141,"label":8},"darooyab",{"pregnancy":166,"lactation":175,"pediatric":183,"geriatric":191},{"level":167,"text":168,"quote":171,"refs":172},"caution",{"fa":169,"en":170},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary Available studies with use of adalimumab during pregnancy do not reliably establish an association between adalimumab and major birth defects.",[173],{"source":35,"section":174},"8.1",{"level":167,"text":176,"quote":179,"refs":180},{"fa":177,"en":178},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary Limited data from case reports in the published literature describe the presence of adalimumab in human milk at infant doses of 0.1% to 1% of the maternal serum concentration.",[181],{"source":35,"section":182},"8.2",{"level":167,"text":184,"quote":187,"refs":188},{"fa":185,"en":186},"برچسب: در JIA از ۲ سالگی و برخی اندیکاسیون‌های دیگر ثابت شده؛ هشدار جعبه‌ای لنفوم و بدخیمی در کودکان و نوجوانان.","Label: established for JIA from 2 y and some other indications; boxed warning of lymphoma and malignancy in children and adolescents.","The safety and effectiveness of HUMIRA have been established for: reducing signs and symptoms of moderately to severely active polyarticular JIA in pediatric patients 2 years of age and older.",[189],{"source":35,"section":190},"8.4",{"level":167,"text":192,"quote":195,"refs":196},{"fa":193,"en":194},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","In patients treated with HUMIRA, closely monitor for the development of infection or malignancy [see Warnings and Precautions ( 5.1 , 5.2 )] .",[197],{"source":35,"section":198},"8.5",1792156160443]